U.S. FDA Approves RINVOQ® (upadacitinib) to Treat Adults and Children 12 Years and Older with Refractory, Moderate to Severe Atopic Dermatitis
Retrieved on:
Friday, January 14, 2022
Atopic dermatitis, Cancer, Giant cell arteritis, Juvenile idiopathic arthritis, Patient, Stroke, Lymphoma, Stomach, Skin cancer, TB, Vein, Allergy, Throat, Virus, Smoker, Psoriasis Area and Severity Index, Enzyme, Degenerative disease, Psoriatic arthritis, AbbVie, Safety, Rash, Scaly, Tears, Death, Surge arrester, Injection, NRS, Human, Disease, Skin, Tongue, Siliceous ooze, TNF, Ulcerative colitis, Time, Bacteria, Artery, Axial spondyloarthritis, Takayasu's arteritis, Infection, Crohn's disease, JAK, Extrapyramidal system, Association, HCP, Dermatitis, Risk, Tell, Rheumatoid arthritis, Shingles, Lung cancer, EASI, Sunlight, Fungus, Tuberculosis, Medical imaging, Synthetic rubber, Pharmaceutical industry, Liquor, Vaccine, Dietary supplement, Birth control, Perfume, Poultry, Copper, Frankincense, Machine tool, EU, Takayasu
RINVOQ is also approved in the EU for adults (15 mg and 30 mg) and adolescents (15 mg) with moderate to severe atopic dermatitis.
Key Points:
- RINVOQ is also approved in the EU for adults (15 mg and 30 mg) and adolescents (15 mg) with moderate to severe atopic dermatitis.
- RINVOQ is safe and effective in children 12 years of age and older weighing at least 88 pounds (40 kg) with atopic dermatitis.
- It is not known if RINVOQ is safe and effective in children under 12 years of age with atopic dermatitis.
- If any of these symptoms occur during treatment with RINVOQ, stop taking RINVOQ and get emergency medical help right away.